Clinical Trial of Nicotinamide Riboside Fails to Meet Primary Endpoint in Parkinson's Disease

A 410-participant, one-year randomized controlled trial of the NAD+ precursor nicotinamide riboside in early Parkinson’s disease failed to demonstrate clinical benefit, challenging the therapeutic rationale of NAD+ augmentation for neurodegenerative motor symptoms.

A multicenter, randomized, placebo-controlled clinical trial evaluated oral nicotinamide riboside in 410 participants with early-stage Parkinson's disease over a one-year period.

The primary endpoint of the trial, which measured changes in self-reported motor and nonmotor symptoms using the MDS-Unified Parkinson’s Disease Rating Scale, was not met.

The study utilized secondary and exploratory outcomes including metabolic analysis of NAD+ levels and dopamine transporter imaging to track disease progression.

Prior clinical studies of NAD+ augmentation had established a compelling biological rationale, leading researchers to design this larger trial to assess whether cellular NAD+ restoration translates to clinical efficacy.

The failure of this study suggests that oral administration of this NAD+ precursor may not yield sufficient neuroprotective or therapeutic efficacy for Parkinson's disease at the tested dosage and duration.

The negative clinical results may lead to increased regulatory and market scrutiny regarding clinical efficacy claims of nicotinamide riboside and other NAD+ precursors.

Companies focused on commercializing consumer NAD+ precursors and researching their clinical endpoints may see a shift in investor confidence concerning neurodegenerative applications.

The release of full exploratory data, specifically metabolic analysis of NAD+ levels and dopamine transporter imaging results, to determine if the precursor achieved target engagement in the central nervous system.